Steps to Successful Management of Immunotherapy Toxicities
Ezra Cohen, MD, FRCPSC, FASCO, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.
Ezra Cohen, MD, FRCPSC, FASCO, professor of medicine, associate director, translational science, Moores Cancer Center, University of California San Diego, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.
Cohen says first, patients need to be educated on the toxicities that could present themselves and should notify their physician immediately should any symptoms appear. Cohen also says that the earlier the symptoms are seen, the easier it is to manage these toxicities and avoid them from escalating to life-threatening situations.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
